相关实验视频

Updated: Jan 7, 2026

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

用rivoceranib和camrelizumab进行的跨动脉化学栓塞治疗BCLCC阶段C肝细胞癌

Rui Zhu¹, Zi-Xuan Zhang², Xin-Zhi Lu¹

¹Department of Interventional Radiology, The First People's Hospital of Linhai, Linhai, China.

Frontiers in oncology

|December 26, 2025

概括

在全身疗法中添加跨动脉化学栓塞 (TACE) 改善了晚期肝癌的治疗结果. 这种组合疗法增强了肝细胞癌 (HCC) 患者的瘤反应和存活率,而不会增加安全问题.

科学领域:

肝胆道手术肝胆道手术
医学瘤学医学瘤学
干预性放射学干预性放射学

背景情况:

晚期肝细胞癌 (HCC) 管理通常涉及跨动脉化学栓塞 (TACE) 和全身治疗.
在巴塞罗那诊所肝癌 (BCLC) 阶段C HCC中,TACE与新型全身药物如rivoceranib和camrelizumab的联合疗效尚未得到充分证实.

研究的目的:

研究TACE与rivoceranib加上camrelizumab在患有晚期HCC (BCLCC阶段C) 的患者中结合的临床疗效和安全性.

主要方法:

一项对2021年1月至2024年12月期间连续治疗的167例BCLC阶段C HCC病例的回顾性分析.
接受TACE加rivoceranib-camrelizumab (n=83) 的组与仅接受rivoceranib-camrelizumab (n=84) 的对照组之间的比较.
评估瘤反应,无进展生存期 (PFS),总生存期 (OS) 和不良事件.

主要成果:

与单独的全身疗法相比,组合疗法组显示出明显更高的部分响应 (39.8%对20.2%) 和客观响应率 (50.6%对29.7%).
在TACE组合组中,PFS (11.0 vs. 9.0个月) 和OS (19.0 vs. 15.0个月) 的中位数显著更长.
联合治疗是改善PFS和OS的独立预测因素,严重不良事件的发生率相似.

结论:

将TACE添加到rivoceranib-camrelizumab治疗中提供了一种有前途的策略,以提高BCLC阶段C HCC中的瘤反应和存活率.
这种综合方法似乎是安全的,具有可管理的不良事件,表明其作为一种有价值的治疗选择的潜力.

关键词:

卡梅里兹马巴姆的摄影肝细胞癌是肝细胞癌.干预干预干预干预干预干预里沃塞拉尼比河是什么意思通过动脉的化学栓塞.

更多相关视频

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...